The improved survival outcomes of patients with non-small-cell lung cancer (NSCLC),
largely owing to the improved control of systemic disease provided by immune-checkpoint …

Introduction: Central nervous system (CNS) metastases represent an important cause of
morbidity and mortality in non-small cell lung cancer (NSCLC) patients. Local approaches of …

Risk of brain metastases (BM) affects a remarkable number of non-small cell lung cancer
(NSCLC) patients, impacting on their quality of life (QoL) and prognosis. While tyrosine …

Significant progress has been made in the treatment of stage IV non-small-cell lung cancer
(NSCLC); however, the prognosis of patients with brain metastases remains poor. Resection …

The therapeutic landscape in patients with advanced non-small-cell lung cancer harboring
oncogenic biomarkers has radically changed with the development of targeted therapies …

Lung cancer represents the most common cause of brain dissemination. Oncogene-
addicted (EGFR-and ALK-positive) non-small cell lung cancers (NSCLCs) are characterized …

Lung cancer is characterized by the highest incidence of solid tumor-related brain
metastases, which are reported with a growing incidence during the last decade. Prognostic …

Simple Summary Central nervous system (CNS) metastases are common and challenging
to manage among patients with non-small cell lung cancer (NSCLC). Here we provide an …

Brain metastases (BM) are common in non-small cell lung cancer patients including in
molecularly selected populations, such as EGFR-mutant and ALK-rearranged tumors. They …

Although central nervous system (CNS) metastases frequently occur in patients with non-
small cell lung cancer (NSCLC), historically these patients have been excluded from clinical …